Literature DB >> 8436774

Nasal secretions in response to acetylsalicylic acid.

M L Kowalski1, M Sliwinska-Kowalska, Y Igarashi, M V White, B Wojciechowska, P Brayton, H Kaulbach, J Rozniecki, M A Kaliner.   

Abstract

BACKGROUND: Acetylsalicylic acid (ASA) induces rhinorrhea in a subset of patients with asthma or chronic rhinosinusitis or both and nasal polyps. The underlying mechanism of the reaction is obscure.
METHODS: To assess the nasal response to ASA challenge, four groups of patients were challenged orally with ASA: group A (10 ASA-sensitive patients); group B (nine patients with nasal polyps and histories of tolerance to ASA); group C (nine ASA-tolerant patients with chronic allergic rhinitis); and group D (eight healthy nonatopic subjects).
RESULTS: Nasal lavages obtained before and after ASA challenge were assayed for proteins (total protein, lactoferrin, lysozyme, albumin) and inflammatory mediators (histamine, prostaglandin D2, and leukotriene C4). ASA challenges induced severe rhinorrhea and congestion and significant increases in mean concentrations of all measured nasal proteins in group A. Histamine and prostaglandin D2 rose, but not significantly. In the two control groups with chronic rhinitis, ASA induced increases in the concentration of proteins and histamine. Leukotriene C4 concentrations were significantly elevated in nasal lavages after ASA challenge in groups A and C only. In group D no symptoms or changes in nasal proteins were observed after aspirin challenge.
CONCLUSIONS: These observations suggest that production of lipoxygenase products of arachidonate may induce glandular secretions that may participate in the clinical changes associated with ASA sensitivity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8436774     DOI: 10.1016/0091-6749(93)90264-g

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  11 in total

Review 1.  Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different?

Authors:  M L Kowalski
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 2.  Clinical features and diagnosis of aspirin induced asthma.

Authors:  A Szczeklik; E Nizankowska
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

Review 3.  Genetics of aspirin induced asthma.

Authors:  M Sanak; A Szczeklik
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

4.  Olfaction and sinonasal symptoms in patients with CRSwNP and AERD and without AERD: a cross-sectional and longitudinal study.

Authors:  V Gudziol; M Michel; C Sonnefeld; D Koschel; T Hummel
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-11-09       Impact factor: 2.503

Review 5.  Pathogenesis of aspirin-exacerbated respiratory disease.

Authors:  Donald D Stevenson; Bruce L Zuraw
Journal:  Clin Rev Allergy Immunol       Date:  2003-04       Impact factor: 8.667

Review 6.  Aspirin sensitivity and desensitization for asthma and sinusitis.

Authors:  Donald D Stevenson
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 7.  Local immunoglobulin production in nasal tissues: A key to pathogenesis in chronic rhinosinusitis with nasal polyps and aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Kathryn E Hulse
Journal:  Ann Allergy Asthma Immunol       Date:  2020-10-13       Impact factor: 6.347

Review 8.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

9.  Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease.

Authors:  Kathleen M Buchheit; Erin Lewis; Deborah Gakpo; Jonathan Hacker; Aaqib Sohail; Faith Taliaferro; Evans Berreondo Giron; Chelsea Asare; Marko Vukovic; Jillian C Bensko; Daniel F Dwyer; Alex K Shalek; Jose Ordovas-Montanes; Tanya M Laidlaw
Journal:  J Allergy Clin Immunol       Date:  2021-06-16       Impact factor: 14.290

10.  Expression of COX-1, COX-2, 5-LOX and CysLT 2 in nasal polyps and bronchial tissue of patients with aspirin exacerbated airway disease.

Authors:  Monique Vorsprach; Christoph Arens; Stephan Knipping; Dörte Jechorek; Sabine Stegemann-Koniszewski; Eva Lücke; Jens Schreiber
Journal:  Allergy Asthma Clin Immunol       Date:  2019-12-26       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.